← Back to Search

SSRI

Fluvoxamine for Post-COVID Syndrome

Phase 2 & 3
Recruiting
Led By Eric Lenze, MD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Taking SSRIs or SNRIs
Unable to provide informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing whether fluvoxamine can help people with long-term COVID-19 symptoms, especially those affecting brain function. The study involves adults who had COVID-19 a while ago and are still experiencing issues like 'brain fog.' The medication works by balancing brain chemicals and supporting the immune system to reduce symptoms. Fluvoxamine has shown potential in reducing inflammation in COVID-19 patients.

Who is the study for?
This trial is for Missouri or Illinois residents aged 25+ who've had COVID-19 symptoms or a positive test at least 3 months ago and are experiencing cognitive issues for the past 2 months. Excluded are those with bipolar disorder on certain meds, severe illnesses, hospitalization at study start, immunocompromised status, taking specific drugs like SSRIs/SNRIs, or enrolled in another COVID-19 medication trial.
What is being tested?
The trial is examining if fluvoxamine can alleviate long-term symptoms of COVID-19. Fluvoxamine is an SSRI approved for OCD that has shown promise in reducing hospitalizations in acute COVID cases. Participants will be assessed to see if their post-COVID condition improves with this treatment.
What are the potential side effects?
Fluvoxamine side effects may include nausea, headaches, sleep disturbances, and sexual dysfunction. It could also potentially interact with other medications leading to increased risks such as serotonin syndrome when combined with similar drugs.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking medication for depression or anxiety.
Select...
I am unable to understand and give consent for treatment.
Select...
I am immunocompromised due to a transplant, high dose steroids, or specific medication.
Select...
I need to be in the hospital to start the study.
Select...
I can perform the study procedures and do not live in Missouri or Illinois.
Select...
I am currently taking donepezil or sertraline.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: FluvoxamineExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fluvoxamine
2020
Completed Phase 4
~3259220

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Fluvoxamine, an SSRI, is being studied for its potential benefits in treating COVID-19 due to its anti-inflammatory properties. SSRIs like fluvoxamine can modulate the immune response by reducing the production of inflammatory cytokines, which are often elevated in severe COVID-19 cases. This can help prevent the cytokine storm, a hyperinflammatory condition that can lead to severe respiratory distress and organ failure. Other common treatments include antiviral agents like nirmatrelvir/ritonavir (Paxlovid), which inhibit viral replication, and corticosteroids like dexamethasone, which reduce inflammation. These treatments are crucial as they target different aspects of the disease process, helping to reduce viral load, manage inflammation, and improve overall patient outcomes.
Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021).Evidence and the Main Adverse Effects Regarding Drug Therapies in the War Against COVID-19.

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,980 Previous Clinical Trials
2,290,980 Total Patients Enrolled
26 Trials studying COVID-19
19,598 Patients Enrolled for COVID-19
Balvi COVID FundUNKNOWN
Eric Lenze, MDPrincipal InvestigatorWashington University School of Medicine
9 Previous Clinical Trials
3,156 Total Patients Enrolled

Media Library

Fluvoxamine (SSRI) Clinical Trial Eligibility Overview. Trial Name: NCT05874037 — Phase 2 & 3
COVID-19 Research Study Groups: Fluvoxamine, Placebo
COVID-19 Clinical Trial 2023: Fluvoxamine Highlights & Side Effects. Trial Name: NCT05874037 — Phase 2 & 3
Fluvoxamine (SSRI) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05874037 — Phase 2 & 3
~75 spots leftby May 2025